Authors:
I de Santiago, C Yau, L Heij, M Middleton, F Markowetz, HI Grabsch, M Dustin, S Sivakumar
Journal name: 
Int J Cancer
Abstract: 
Pancreatic ductal adenocarcinoma (PDAC) is the most common malignancy of the pancreas and has one of the highest mortality rates of any cancer type with a 5-year survival rate of <5%. Recent studies of PDAC have provided several transcriptomic classifications based on separate analyses of individual patient cohorts. There is a need to provide a unified transcriptomic PDAC classification driven by therapeutically relevant biologic rationale to inform future treatment strategies. Here, we used an integrative meta-analysis of 353 patients from four different studies to derive a PDAC classification based on immunologic parameters. This consensus clustering approach indicated transcriptomic signatures based on immune infiltrate classified as adaptive, innate and immune-exclusion subtypes. This reveals the existence of microenvironmental interpatient heterogeneity within PDAC and could serve to drive novel therapeutic strategies in PDAC including immune modulation approaches to treating this disease. This article is protected by copyright. All rights reserved.
DOI: 
http://doi.org/10.1002/ijc.32186
Research group: 
Markowetz Group
E-pub date: 
31 Jan 2019
Users with this publication listed: 
Florian Markowetz